Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

This study has been terminated.
Information provided by:
Genaera Corporation Identifier:
First received: August 16, 2004
Last updated: November 27, 2007
Last verified: November 2007
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.

Condition Intervention Phase
Macular Degeneration
Drug: MSI-1256F (Squalamine Lactate)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Genaera Corporation:

Estimated Enrollment: 120
Study Start Date: August 2004
Study Completion Date: May 2007

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with a diagnosis of "wet" age-related macular degeneration

Exclusion Criteria:

  • Prior treatment of "wet" age-related macular degeneration in the affected eye in the past 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00089830

United States, Pennsylvania
Genaera Corporation
Plymouth Meeting, Pennsylvania, United States, 19462
Sponsors and Collaborators
Genaera Corporation
  More Information Identifier: NCT00089830     History of Changes
Other Study ID Numbers: MSI-1256F-209 
Study First Received: August 16, 2004
Last Updated: November 27, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Genaera Corporation:
Subfoveal Choroidal Neovascularization
Squalamine Lactate

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors processed this record on October 21, 2016